GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-07-03| Technology

BioAutoMATED: A Breakthrough AutoML Platform for Biological Sequence Analysis

by GeneOnline
Share To

Incorporating machine learning (ML) into biological research has long been a challenge for many biologists due to the complex design choices underlying ML models. However, a groundbreaking study introduces BioAutoMATED, an automated machine learning (AutoML) platform specifically tailored for analyzing biological sequences. This platform overcomes the limitations of traditional AutoML algorithms by seamlessly integrating multiple methods and offering a unified framework for analyzing, interpreting, and designing biological sequences. The potential of BioAutoMATED was demonstrated through a series of experiments, showcasing its ability to predict gene regulation, peptide-drug interactions, and glycan annotation, as well as to optimize synthetic biology components.

Related article: Sanofi Goes “All In” to Lead the AI Revolution in Pharmaceutical Industry

Accelerating Sequence Analysis and Design

The researchers behind BioAutoMATED initially explored the platform’s capabilities by investigating the impact of altering the ribosome binding site sequence on ribosome binding efficiency in E. coli. The results were impressive, as BioAutoMATED successfully identified a DeepSwarm algorithm-generated model that accurately predicted translation efficiency. Notably, this model achieved comparable performance to those created by professional ML experts but required only a fraction of the time and code input. Additionally, BioAutoMATED provided insights into the sequence characteristics crucial for determining translation efficiency and even facilitated the design of novel sequences for experimental testing.

Continuing their exploration, the team leveraged BioAutoMATED to analyze peptide and glycan sequences, yielding valuable insights into these biological components. The platform proved adept at identifying key amino acids influencing antibody-drug binding in peptide sequences and effectively classifying different types of glycans into immunogenic and non-immunogenic groups based on their sequences.

BioAutoMATED’s Insights into Peptide and Glycan Sequences

Lead researcher Katie Collins from the University of Cambridge emphasized the broad benefits of BioAutoMATED, stating, “It enables users to recognize patterns, ask better questions, and obtain quick answers from biological data within a single framework, without requiring extensive ML expertise.” While all models generated by BioAutoMATED should be experimentally validated, the researchers envision its integration into an expanding repertoire of AutoML tools, potentially extending its applications beyond biological sequences to other sequence-like objects, such as fingerprints.

As machine learning and artificial intelligence tools gain popularity, BioAutoMATED emerges as a user-friendly breakthrough, empowering the next generation of biologists to delve into the intricate mechanisms of life more efficiently. With its ability to automate sequence modeling, this cutting-edge platform holds tremendous promise for advancing research in the life sciences and beyond.

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Revolutionary Technology Aims to Detect and Prevent Dementia and Mental Illness
2023-09-22
Ultima Genomics Promises $100 Genome After Raising $600 Million
2022-06-01
No Real-Life Placebo Required – Deriving Virtual Control Group Data by Machine Learning
2022-03-16
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top